J. Goldman & Co’s Regeneron Pharmaceuticals REGN Stock Holding History

J. Goldman & Co’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-4,000	Closed	-$3.09M	–	889
2026 Q1	$3.09M	Sell	4,000 -6,000	-60%	-$4.59M	0.09%	252
2025 Q4	$7.72M	Hold	10,000	–	–	0.2%	142
2025 Q3	$5.62M	Buy	10,000 +4,000	+67%	+$2.26M	0.14%	188
2025 Q2	$3.15M	Buy	+6,000	New	+$3.35M	0.08%	245
2024 Q4	–	Sell	-12,700	Closed	-$13.4M	–	592
2024 Q3	$13.4M	Buy	12,700 +10,700	+535%	+$11.9M	0.37%	81
2024 Q2	$2.1M	Buy	+2,000	New	+$1.94M	0.06%	248
2023 Q4	–	Sell	-15,600	Closed	-$12.8M	–	450
2023 Q3	$12.8M	Buy	+15,600	New	+$12.3M	0.45%	69
2023 Q2	–	Sell	-8,700	Closed	-$7.15M	–	472
2023 Q1	$7.15M	Buy	+8,700	New	+$6.56M	0.29%	108
2022 Q4	–	Sell	-8,000	Closed	-$5.51M	–	470
2022 Q3	$5.51M	Buy	+8,000	New	+$5.04M	0.26%	113

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

J. Goldman & Co's REGN Position: Q2 2026 in Review

J. Goldman & Co reduced its Regeneron Pharmaceuticals (REGN) stake by 57% in Q2 2026, selling an estimated $6.35M and leaving 6,936 shares worth $4.32M. The position accounts for 0.11% of the portfolio, ranked #224.

J. Goldman & Co first reported a position in REGN in Q2 2022 and has held it in 17 quarters since. The position peaked at $40.1M in Q4 2023. 1,340 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

J. Goldman & Co held 6,936 shares of Regeneron Pharmaceuticals worth $4.32M as of Q2 2026.
J. Goldman & Co sold 9,332 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $6.35M.
Regeneron Pharmaceuticals made up 0.11% of J. Goldman & Co's portfolio in Q2 2026, its #224 holding.
J. Goldman & Co first reported a position in Regeneron Pharmaceuticals in Q2 2022 and has held it in 17 quarters since.
J. Goldman & Co's Regeneron Pharmaceuticals position peaked at $40.1M in Q4 2023.
1,340 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.